Alpha Cognition Reports Strong Q2 Growth on ZUNVEYL Momentum
Event summary
- ZUNVEYL revenue grew 71% QoQ to $6.0M in Q2 2026, with bottles dispensed increasing 37% to 8,294.
- Prescriber base expanded by 26% sequentially to 1,347 healthcare professionals.
- Repeat prescribers rose 29% QoQ to 1,024, with 76% of Q2 prescribers generating multiple prescriptions.
- Operating loss narrowed to $7.8M from $8.4M YoY despite increased commercial investment.
The big picture
Alpha Cognition's Q2 results demonstrate strong commercial traction for ZUNVEYL in the competitive Alzheimer's disease market. The company's focus on long-term care facility penetration and repeat prescriber growth positions it well against established cholinesterase inhibitors like donepezil and rivastigmine. With disciplined capital allocation and a robust clinical development pipeline, Alpha Cognition is executing its strategy to become a key player in neurodegenerative disorder therapeutics.
What we're watching
- Commercial Execution
- Whether Alpha Cognition can sustain its strong prescriber growth and repeat prescription rates through H2 2026.
- Clinical Evidence
- The pace at which CONVERGE and RESOLVE studies will provide additional real-world evidence to support ZUNVEYL's differentiated profile.
- Formulation Pipeline
- How the sublingual development program progresses toward clinic in 2027, potentially expanding treatment options for severe Alzheimer's patients.
Related topics